Registered outcomes23

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 20 of 23

List	Outcome	Time frame
Primary	Treatment of bleeding episodes at clinic/hospital: Treatment efficacy evaluation for each treatment modality: excellent, effective, partly effective, ineffective, or not evaluable	Evaluated at 6 hours
Primary	Treatment of bleeding episodes at clinic/hospital: Treatment efficacy evaluation for each treatment modality: excellent, effective, partly effective, ineffective, or not evaluable	Evaluated after 30 days
Primary	Treatment of bleeding episodes at clinic/hospital: Time to achieve arrest of bleeding	Time to achieve arrest of bleeding
Primary	Treatment of bleeding episodes at clinic/hospital: Number of re-bleeding episodes	Within 5 days after first product administration
Primary	Treatment of bleeding episodes at home: Treatment efficacy evaluation for each treatment modality: excellent, effective, partly effective, ineffective, or not evaluable	Evaluated at 6 hours
Primary	Treatment of bleeding episodes at home: Time to achieve arrest of bleeding	Time to achieve arrest of bleeding
Primary	Treatment efficacy (of first and/or second treatment modality) evaluated after surgery: good, partially effective, not evaluable, or ineffective	After surgery
Primary	Treatment efficacy (of first and/or second treatment modality) evaluated after surgery: good, partially effective, not evaluable, or ineffective	Evaluated after 30 days
Primary	Estimated blood loss volume	During surgery/delivery
Primary	Number of red blood cell units administered	During surgery
Primary	Number of days spent in hospital	Until last data collection (20 Jan 2012)
Primary	Number of re-bleeding episodes (associated with the surgery)	Within 5 days after surgery
Primary	Prophylactic treatment efficacy evaluation: excellent, excellent, partially effective, or effective	30 days after first prophylaxis dose
Secondary	Number of bleeding episodes during prophylaxis per year	Up to one year
Secondary	Number of intensive care unit (ICU) and/or the number of ward days	After first haemostatic product administration until day 30
Secondary	Mortality	Within a 30-day (follow-up) period
Secondary	Changes in laboratory parameters (prothombin time/international normalized ratio, activated partial thromboplastin time, FVII clotting activity, platelet count, fibrinogen)	Prior to dosing
Secondary	Changes in laboratory parameters (prothombin time/international normalized ratio, activated partial thromboplastin time, FVII clotting activity, platelet count, fibrinogen)	After 15 minutes
Secondary	Changes in laboratory parameters (prothombin time/international normalized ratio, activated partial thromboplastin time, FVII clotting activity, platelet count, fibrinogen)	After 30 days
Secondary	Presence of and/or de novo appearance of inhibiting antibodies to FVII	Prior to dosing

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01779921/registered

API reference For AI assistants

Registered outcomes23

Sources 3

Read this list from software.